BlueCross BlueShield of Tennessee Medical Policy Manual

Prostate Specific Antigen (PSA)

Does not apply to BlueCare.

DESCRIPTION

The prostate specific antigen (PSA) test measures serum levels of the prostate cancer-associated antigen. The test is used to monitor for progression or regression of prostate cancer after therapy. Although increased serum PSA can be an early indicator of prostate cancer, other conditions such as benign prostatic hypertrophy (BPH) can also cause an elevation in the serum PSA level. Measurement of different molecular forms of PSA (free or protein-bound) can increase specificity of the PSA test.

POLICY

See also:  Novel Biomarkers for the Diagnosis and Management of Prostate Cancer

MEDICAL APPROPRIATENESS

IMPORTANT REMINDERS

This medical policy does not apply to BlueCare.

ADDITIONAL INFORMATION

Compliant with Tenn. Code Ann. § 56-7-2354 (2017) - 56-7-2354. Early detection of prostate cancer.

(a) Every contract that provides for hospital, surgical or medical care shall provide, upon the recommendation of a physician, coverage for the early detection of prostate cancer for men fifty (50) years of age and older and other men if a physician determines that early detection for prostate cancer is medically necessary.

SOURCES

American Cancer Society. (2017) Recommendations for prostate cancer early detection. Retrieved July 12, 2017 from https://www.cancer.org/cancer/prostate-cancer/early-detection/acs-recommendations.html.

American Urological Association (AUA) / American Society for Radiation Oncology (ASTRO) / Society of Urologic Oncology (SUO) (2017, April) Clinically localized prostate cancer: AUA/ASTRO/SUO guideline. Retrieved December 4, 2017 from www.auanet.org/guidelines.

Center for Medicare and Medicaid Services. CMS.gov. (NCD) for prostate specific antigen (190.31) Retrieved January 8, 2016 from https://www.cms.gov.

National Comprehensive Cancer Network. (2017, June). NCCN clinical practice guidelines in oncology™. Prostate cancer early detection (V.2.2017) Retrieved December 6, 2017 from www.nccn.org.

Tennessee Code: Title 56 Insurance. Chapter 7 Policies and Policyholders: Part 23 Mandated Insurer or Plan Coverage, 56-7-2354. 2017. Early detection of prostate cancer. Retrieved December 6,, 2017 from http://www.lexisnexis.com.

U. S. Food and Drug Administration. (2004, February). Center for Devices and Radiological Health. Pre-market approval P040008. Retrieved January 8, 2016 from http://www.accessdata.fda.gov.

U. S. Preventive Services Task Force. (2012, May). Screening for prostate cancer: U.S. preventive services task force recommendation statement. Retrieved July 12, 2017 from https://www.uspreventiveservicestaskforce.org.

ORIGINAL EFFECTIVE DATE:  7/1995

MOST RECENT REVIEW DATE:  3/1/2018

ID_BT

Policies included in the Medical Policy Manual are not intended to certify coverage availability. They are medical determinations about a particular technology, service, drug, etc. While a policy or technology may be medically necessary, it could be excluded in a member's benefit plan. Please check with the appropriate claims department to determine if the service in question is a covered service under a particular benefit plan. Use of the Medical Policy Manual is not intended to replace independent medical judgment for treatment of individuals. The content on this Web site is not intended to be a substitute for professional medical advice in any way. Always seek the advice of your physician or other qualified health care provider if you have questions regarding a medical condition or treatment.

This document has been classified as public information.